$5.03
1.86% today
Nasdaq, Jul 23, 06:18 pm CET
ISIN
US98422L1070
Symbol
XERS

Xeris Pharmaceuticals Inc Stock News

Positive
Seeking Alpha
about one month ago
Compared to other biotech companies, Xeris Biopharma Holdings Inc. is a company that has successfully launched products that are already generating revenue. As the company's revenue is expected to grow significantly by 2030, the stock price may rise accordingly. Moreover, XP-8121 may serve as a catalyst for higher stock valuation.
Neutral
Business Wire
about 2 months ago
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, will host its first-ever Analyst and Investor Day today to showcase its strategy for sustainable growth and value creation. “We have built a strong foundation thro...
Neutral
Business Wire
2 months ago
CHICAGO--(BUSINESS WIRE)--Xeris Announces Details for Analyst & Investor Day.
Neutral
Seeking Alpha
3 months ago
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q1 2025 Results Conference Call May 8, 2025 8:30 AM ET Company Participants Allison Wey - SVP of IR, Corporate Communications John Shannon - CEO Steve Pieper - CFO Conference Call Participants David Amsellem - Piper Sandler Eason Lee - Leerink Partners Jason Dorr - Oppenheimer Chase Knickerbocker - Craig-Hallum Operator Good morning. Thank you for a...
Neutral
Business Wire
3 months ago
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2025, and updated its fiscal 2025 total revenue guidance. “We're very pleased with our stro...
Negative
Seeking Alpha
3 months ago
Xeris Biopharma Holdings, Inc. has shown consistent double-digit growth and is expected to continue this trend, with Q1 earnings projected to drive the share price higher. Key metrics to watch include Gvoke and Recorlev revenues, EPS, adjusted EBITDA, and cash flow, as these will determine Xeris's path to profitability. Risks include potential underperformance in product revenue, rising SG&A ex...
Neutral
Business Wire
3 months ago
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025.
Neutral
Business Wire
4 months ago
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced changes to its board of directors. Ricki Fairley has resigned from the board in light of other commitments, effective immediately. The Board of ...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today